1. Home
  2. Clinical Topics
  3. Women's Health
  4. Aging
  5. Easing the anguish of Alzheimer’s disease
AgingClinical TopicsFeaturesNeurology

Easing the anguish of Alzheimer’s disease


Most of us have seen the alarming figures on Alzheimer’s disease (AD): An estimated 4.5 million Americans have it. What’s more, this statistic may be an understatement because the disease often goes unrecognized. Some experts put the true incidence at nearly 6.5 million. As the U.S. population ages, the burden of AD is bound to rise substantially. By 2050, AD may affect 16 million Americans.

AD is the leading cause of dementia, accounting for about two-thirds of dementia cases. It strikes approximately 10% of persons older than age 65. Incidence doubles every 5 years until 50% of adults older than age 90 have it.

Although onset usually comes after age 60, some people get a rare familial early-onset form. The disease occurs in three stages—mild, moderate, and severe. (See Staging Alzheimer’s disease in PDF format by clicking the download now button.)

Researchers understand the disease better than they did 20 years ago and are working on ways to prevent it, treat it, and delay its onset. Nonetheless, with its relentless clinical course, AD takes an enormous toll on both caregivers and the healthcare system. This article defines AD, explores risk factors and potential causes, describes its diagnosis and treatment, and discusses how to help family members and others who care for AD patients.

Theories about the cause
The exact cause of the disease remains unknown, but several theories exist:

  • The finding of amyloid plaques in the brains of AD patients led to the amyloid hypothesis, which proposes that AD stems from accumulation of amyloid beta-peptide in the brain. Other proteins associated with plaque formation include apolipoprotein E, complement proteins, and cytokines.
  • According to the tau hypothesis, AD results from dysfunction of the tau protein.
  • The vascular hypothesis grew out of the finding that many AD patients also have vascular dementia. It proposes that cardiovascular and cerebrovascular disease and other insults cause endothelial damage.

Improper balance and function of nerve growth factors and inflammation also may play a part in AD.

Risk factors
Risk factors for AD include advancing age, female gender, low educational level, and lack of mental stimulation. Other possible factors include diabetes mellitus, alcoholism, depression, head injuries (related to inflammation and endothelial changes stemming from brain trauma), and a history of migraines. Researchers believe AD may run in families, although they don’t know why some people with a family history get it while others don’t.

Can AD be prevented?
With the cause of AD still unknown, prevention is a challenge. Minimizing modifiable risk factors may help in some cases.

Staying mentally, physically, and socially active is the mainstay of risk-factor reduction. The Alzheim­er’s Association emphasizes eating a healthy diet. Some experts recommend controlling cardiovascular risk factors (such as weight, smoking, cholesterol levels, and blood pressure), taking steps to prevent diabetes mellitus, and avoiding head injuries (as by wearing helmets and taking other precautions as necessary).

Assessment and diagnosis
The sooner AD is diagnosed, the sooner treatment can begin. AD has a gradual onset and may not be apparent for 5 to 15 years. Signs and symptoms typically include progressive deterioration in memory, learning, decision making, communicating, and performing normal daily activities. Many patients also experience behavioral and personality changes, depression, insomnia, delusions, and even hallucinations.

In a patient with suspected AD, the history is crucial and should reflect a gradual cognitive decline. Diagnosis rests on history, physical and mental assessment findings, and diagnostic test results. (See Diagnostic criteria for Alzheimer’s disease in PDF format by clicking the download now button.) Memory impairment and other cognitive problems may make the patient an unreliable information source, so if necessary obtain the history from family members or friends.

Neurologic testing, including cognition testing, should be performed as part of the complete physical assessment. (See Key cognitive tests for Alzheimer’s disease in PDF format by clicking the download now button.) If the patient’s history, physical examination, and cognitive test results suggest AD, the following laboratory tests may be done to aid diagnosis and rule out common medical causes of cognitive decline:

  • complete blood count and vitamin B12 level, to rule out anemia
  • thyroid studies, to rule out thyroid disease
  • chemistry panel, to rule out diabetes mellitus and renal and hepatic dysfunction
  • human immunodeficiency virus and syphilis testing (in at-risk patients)
  • toxicology panel, urinalysis, and lumbar puncture (depending on signs and symptoms)
  • brain imaging studies, such as computed tomography or magnetic resonance imaging.

However, no truly reliable antemortem test for AD exists. So even after these tests are done, diagnosis rests on clinical findings.

Although AD can’t be cured, several drugs may help improve cognitive function for a limited time. If given early enough in the disease course, they may help the patient continue functioning as long as possible and prolong the time that he or she can be cared for at home. Other drugs may be given to manage mood and behavioral problems. Despite these pharmacologic treatments, though, AD eventually progresses.

Drugs to slow disease progression
Two major groups of drugs are used to slow AD progression—acetylcholinesterase inhibitors (AChEIs) and N-methyl-D-aspartate (NMDA) receptor antagonists.

In most clinical trials showing benefits from AChEIs, therapy was short-term (up to 3 or 6 months) and used only in patients with mild to moderate AD. These studies found the drugs brought modest cognitive improvement and slowed disease progression; however, long-term studies haven’t shown the same benefit. Donepezil (Aricept) is the only AChEI with some benefit in severe AD, but no AChEI has clear benefits over another. To help determine if an AChEI will be effective, a trial of at least 6 months is recommended. These drugs cost $6 a day on average, which may be prohibitively expensive for uninsured patients.

Memantine (Namenda), the only NMDA receptor antagonist currently available, can be used alone, as monotherapy, or in combination with donepezil; the combination seems to have synergistic effects.

In a patient currently receiving an AChEI, the clinician may decide memantine would bring greater benefit. If so, the patient should take both drugs for 1 month before stopping the AChEI to avoid discontinuation syndrome. Memantine is nearly as expensive as an AChEI—about $5 a day. (See Drugs used to treat Alz­heimer’s disease in PDF format by clicking the download now button.)

Managing psychotic and depressive symptoms
Psychotic behavior and depressive symptoms must be treated cautiously. In some cases, AD drugs improve psychotic behavior. But some anti­psychotics may worsen AD symptoms, increase the risk of stroke (possibly by causing weight gain and promoting diabetes development), and prolong the QTc interval.

What’s more, combining AChEIs with antipsychotics may heighten the risk of extrapyramidal symptoms. First-generation antipsychotics are likely to cause neuroleptic malignant syndrome and tardive dyskinesia as well as extrapyramidal symptoms. Because of these potential concerns and lack of definitive studies showing superior benefit from antipsychotics, experts recommend avoiding these drugs in AD patients.

Selective serotonin reuptake inhibitors may be useful in patients with suspected or diagnosed major depression.

Controlling risk factors
Uncontrolled cardiovascular disease and uncontrolled diabetes may speed amyloid deposition, possibly accelerating AD development or causing AD to worsen. Therefore, many clinicians recommend measures to control cardiovascular disease (especially hypertension and hyperlipidemia) to help minimize its effects on dementia. To help stave off stroke, some recommend low-dose aspirin.

Helping the family manage home care
A family that plans to care for an AD patient at home will need a great deal of support. As appropriate, arrange for a visit by a home health nurse, an occupational therapist, or another healthcare professional to evaluate the home for safety concerns (such as dangerous stairs, poor lighting, and loose rugs).

To help family members establish a routine for activities of daily living (ADLs), provide simple instructions on bathing, dressing, feeding, taking medications, exercising, and bedtime rituals. Write down the steps of each routine and post the instructions in an obvious place.

Providing ongoing care
When a patient has AD, you have two sets of patients—the one diagnosed with AD and the family members or others providing care at home. Giving caregivers support and information is an essential part of managing AD. Help them obtain social services and the other resources they need to assess living conditions, develop home care plans, and evaluate and perform ongoing assessment of both the patient and caregiver.

Caring for a patient with AD takes an enormous mental, emotional, physical, and financial toll. Family members witness their loved one—once full of life, vigor, and intelligence—grow progressively more impaired, become increasingly agitated, manifest abusive behavior, and eventually depend on others completely. Family members caring for AD patients have extremely high rates of depression and “burnout” and suffer more frequent illnesses than the general population.

As the patient drains time, resources, and energy, family members’ personal, social, and work lives deteriorate. They may need support and medication for depression. The increased stress and burden they’re under may even cause them to become physically abusive toward the patient, so be sure to assess for this problem regularly.

The right approach. Teach caregivers the right way to approach the AD patient—by moving and speaking slowly, using simple words, and repeating these words frequently if needed. If the patient becomes agitated when performing a task, advise caregivers to back off, take deep breaths, and begin the task again, but more slowly this time. Caution them not to argue with the patient, correct the patient’s delusions, try to teach the patient new things, or get upset in front of the patient. Point out that the patient may internalize the caregiver’s frustration or outburst of emotions and then display these feelings outwardly as agitation, aggression, or anger.

Remind caregivers that AD patients don’t remember that they forgot or can’t remember. Point out that reorienting the patient is acceptable to a point, but should be kept to the “here and now.” If the patient asks the same question repeatedly, recommend that the caregiver answer simply each time, then step away for a moment (if it’s safe to do so) or use another diversionary technique to avoid getting upset with the patient. Advise caregivers to find a place where they can go or someone they can call if they feel they’re nearing the point of abusing the patient or “going crazy.” Urge them to seek or accept assistance from relatives, friends, church members, or other available sources.

Does the patient belong in a long-term care facility?
Deciding whether to place a patient in an extended-care facility can be agonizing for the family, arousing feelings of guilt and imposing a financial burden. To help objectify the need for such placement, healthcare providers may use assessment tools such as the Katz Index of Independence in ADLs and the Instrumental ADL scale. These tools assess six areas—bathing, toileting, dressing, transferring, continence, and feeding.

Relentless disease, rising burden
AD involves many body systems other than the neurologic. The disease and its eventual effects on all ADLs (including nutrition, exercise, and hygiene) may directly influence the musculoskeletal, integumentary, and cardiovascular systems. The patient’s decline may be slow, increasing caregiver burden. With our aging population and the rising AD incidence, this burden is likely to affect all of us in some way and to some degree.

As nurses, we sometimes get caught up in giving caregivers standard information about AD and the patient’s prescribed medications. Try to go at least one step further by providing simple instructions on how to manage the patient on a day-to-day basis and how to take care of themselves. Such practical advice may benefit them even more than your cognitive nursing knowledge and skills.

Selected references
Abramowicz M, ed. Drugs for cognitive loss and dementia. Treat Guidel Med Lett. 2007;5(54):9-14.

Beatty GE. Shedding light on Alzheimer’s disease. Nurse Pract. 2006;31(9):32-43.

Callone P. Vasiloff B, Brumbach R, Kudlacik C, Manternach J. A caregiver’s guide to Alz­heimer’s Disease: 300 tips for making life easier. New York, NY: Demos Medical Publishing; 2006.

Kane T. Alzheimer’s disease. Nursing2007. 2007;37(6):50-51.

Mayhew M. The growing challenge of Alz­heimer disease, part 1. Nurse Practitioner Journal. 2005;1(2):74-83.

Mayhew M. The growing challenge of Alz­heimer disease, part 2. Nurse Practitioner Journal. 2005;1(3):149-156.

Visit www.AmericanNurseToday.com for a complete list of selected references and a list of resources on AD.

Susan Simmons Holcomb is a Nurse Practitioner at Walk-In Health Care of Olathe in Olathe, Kansas, and Quivira Family Care in Overland Park, Kansas. The author does not have any financial arrangements or affiliations with any corporations offering financial support or educational grants for continuing nursing education activities.

Leave a Reply

Your email address will not be published. Required fields are marked *

Fill out this field
Fill out this field
Please enter a valid email address.

cheryl meeGet your free access to the exclusive newsletter of American Nurse Journal and gain insights for your nursing practice.

NurseLine Newsletter

  • Hidden

*By submitting your e-mail, you are opting in to receiving information from Healthcom Media and Affiliates. The details, including your email address/mobile number, may be used to keep you informed about future products and services.


Recent Posts